Advances in Care

• Solving Long Term Side Effects of Chemotherapy Cancer Treatments

  On this episode of Advances in Care, host Erin Welsh hears from Dr. Meghna Trivedi, an oncologist at NewYork-Presbyterian and Columbia, who is spearheading new research to assess cancer patients’ risk of developing chemotherapy induced peripheral neuropathy–an all too common side effect of cancer treatment.Dr. Trivedi describes a study that she and her team undertook to identify and assess patient risk for developing a specific type of chemotherapy-induced neuropathy called TIPN, which is caused by taxanes, a commonly used chemotherapy drug. Based on this SWOG trial, known as S1714, physicians are better able to monitor at-risk patients for these side effects and adjust their treatment regimens accordingly.Then, Dr. Trivedi explains how her team–also led by Dr. Daniel Hertz, PharmD, PhD at the University of Michigan–was recently awarded a prestigious R37 grant to identify a biomarker for TIPN.  This study, which she co-leads with Dr. Daniel Hertz, PharmD, PhD at the University of Michigan, will help doctors understand the mechanisms for why TIPN develops in the first place, and will be a critical step forward in creating targeted therapies to treat this disease before it starts.Finally, Dr. Trivedi dives into the clinical trials her team is currently conducting to identify new therapeutic approaches to address and prevent the effects of neuropathy, such as cryotherapy.***Dr. Meghna Trivedi, is a medical oncologist at NewYork-Presbyterian and co-leads the Hereditary Breast and Ovarian Cancer Program at Columbia’s Herbert Irving Comprehensive Cancer Center, a comprehensive, multi-disciplinary initiative aimed at screening, preventing, diagnosing, and treating hereditary breast and ovarian cancer. This innovative program brings together the resources of a world-renowned academic institution, including cutting-edge genomic testing, clinical trials, and experts in hereditary cancers across different specialties. Dr. Trivedi’s research and care expertise also includes cancer genetics and genomics, precision medicine, and chemotherapy induced peripheral neuropathy. She is the principal investigator on several clinical trials, and has authored numerous publications in leading peer-reviewed journals.To learn more about the SWOG trial visit swog.org/clinical-trials/s1714For more information visit nyp.org/Advances

  --------  

  16:07

  --------

  16:07
• Pioneering a First in Robotic Liver Transplant

  On this episode of Advances in Care, host Erin Welsh hears from Dr. Juan P. Rocca, a transplant surgeon at NewYork-Presbyterian and Weill Cornell Medicine, who recently led the first fully robotic liver transplant in New York.Dr. Rocca details the recent developments in robotic surgery at Weill Cornell Medicine’s Division of Liver Transplantation and Hepatobiliary Surgery, including an ongoing push to advance from laparoscopic and open surgical methods, and now to robotics. He explains why the robotic approach is optimal for complex liver surgeries, and discusses how he and his team have been training to make robotic living donor hepatectomies a standard in their department.Then, Dr. Rocca breaks down the process of the liver transplant operation that became the first fully robotic execution in New York. He describes the most critical steps of the procedure, how it felt to achieve this milestone, and the example that he hopes to set for other institutions beyond NewYork-Presbyterian and Weill Cornell Medicine.***Dr. Juan Rocca is the Surgical Director of the Weill Cornell Liver Cancer Program and an attending surgeon in the Division of Liver Transplantation and Hepatobiliary Surgery at NewYork-Presbyterian and Weill Cornell Medicine. He was an early adopter of laparoscopic techniques for major hepatectomy and later transitioned to robotic surgery for complex liver procedures in patients with chronic liver disease. At Weill Cornell Medicine, he led the development of a comprehensive robotic liver surgery program, encompassing liver cancer resections, living liver donation, and the state's first fully robotic liver transplantFor more information visit nyp.org/Advances

  --------  

  17:53

  --------

  17:53
• Rise in Early-Onset Colon Cancer Being Studied Through Single-Cell Sequencing

  On this episode of Advances in Care, host Erin Welsh and Dr. Joel Gabre, a gastroenterologist at NewYork-Presbyterian and Columbia who specializes in cancer care, discuss the ongoing rise in colorectal cancer rates among younger individuals. Dr. Gabre lays out trends observed by the medical community in colorectal cancer rates, including the increasing likelihood by birth cohort for patients to develop this disease. He also talks about the main differences in colorectal cancer for patients from these different cohorts, most notably the location where cancers are likely to develop in the colon.Dr. Gabre also shares some of the leading hypotheses for why colon cancer rates are rising in younger people, and that clinicians and researchers are focused on searching for answers to improve prevention and treatment options. He gets into the importance of the western diet in developing these forms of cancer and shares details about his team’s recent findings regarding changes at the cellular level that could be contributing to the accelerated growth of these cancers.Finally, Dr. Gabre speaks to his personal experiences as a gastroenterologist who has seen first hand the rise in colon cancer rates among his patients. He shares a story of what motivated him to begin researching the cellular mechanisms driving colorectal cancer in young people, with the hope of finding a solution.***Dr. Joel Gabre is a gastroenterologist and GI cancer genetics specialist interested in studying diseases of the upper GI tract with particular focus on the esophagus. He completed his undergraduate degree at Johns Hopkins University in biophysics, medical degree at the University of Maryland, internal medicine residency at the University of Cincinnati, and gastroenterology fellowship and post-doctoral research fellowship at the University of Pennsylvania, where he was chief GI fellow. He currently serves as Assistant Professor of Medicine at Columbia University Irving Medical Center in the Division of Digestive and Liver Diseases and as a member of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian and Columbia.For more information visit nyp.org/Advances

  --------  

  15:46

  --------

  15:46
• How GLP-1s Provide New Options to Manage Heart Disease

  On this episode of Advances in Care, host Erin Welsh talks to Dr. David Majure, a cardiologist and heart failure specialist at NewYork-Presbyterian and Weill Cornell Medicine. Together they discuss the rapid rise in GLP-1 research over the past few years, indicating new applications for these therapies to help a wide variety of patients. They explore how GLP-1s work on a molecular level, and how using them to treat diabetes revealed other potential cardiovascular benefits.Dr. Majure highlights several  recent studies that explore the effects of semaglutide and tirzepitide on patients with heart failure, particularly those with preserved ejection fraction. This new research demonstrates that GLP-1s can be an effective treatment beyond diabetes, helping with weight management and cardiovascular disease. Dr. Majure breaks down what effects doctors can expect to see in patients who are prescribed GLP-1s, including the difference in outcomes between semaglutide and tirzepatide. He also notes the potential risk factors, cautioning that while these medications are effective, the focus in addressing heart disease should always remain on prevention.***Dr. David Majure is the Medical Director of the Heart Transplant Service at NewYork-Presbyterian and Weill Cornell Medicine. He specializes in the care of patients with heart failure, patients requiring or who have a heart transplant or ventricular assist device (LVAD), and patients with pulmonary hypertension. He has contributed extensively to research and has served as principal investigator in multiple clinical trials, exploring all aspects of advanced heart failure. Dr. Majure has been recognized as a Castle Connolly Top Doctor since 2020.For more information visit nyp.org/Advances

  --------  

  15:25

  --------

  15:25
• Developing Precise Diagnostics for this Common Genetic Heart Disease

  On this episode of Advances in Care, host Erin Welsh and cardiologist Dr. Diala Steitieh discuss the current landscape of care for hypertrophic cardiomyopathy — or HCM — the most common genetic heart disorder. Dr. Steitieh outlines the advantages of genetic screenings for patients who have HCM, along with the symptoms and risks if the condition is left undiagnosed or unmanaged.She expands on the importance of understanding obstructive vs. non-obstructive conditions and the importance of making a precise diagnosis to get a clear sense of each patient’s severity. Dr. Steitieh and her team recently implemented a new approach to their diagnostic imaging protocol called goal-directed Valsalva. With this emerging tool in the landscape of cardiology, they are able to get a better sense of an obstruction impacting blood flow, and ultimately offer a wider variety of treatment options.Beyond diagnosis, Dr. Steitieh also shares her excitement about updates to the management of HCM, including recently approved drugs and new guidelines regarding sports & exercise. She and her team at Weill Cornell Medicine are in the process of becoming a designated Hypertrophic Cardiomyopathy Association Center of Excellence, a development that Dr. Steitieh hopes will improve access to care for patients in New York and beyond.***Dr. Diala Steitieh is an Assistant Professor of Clinical Medicine, and the Director of the Hypertrophic Cardiomyopathy program in the Division of Cardiology at Weill Cornell Medical College and New York Presbyterian Hospital. She has a background in sports cardiology and also cares for patients with a wide array of cardiovascular diseases, including coronary disease and valvular heart disease. Dr. Steitieh also serves as an attending physician on the inpatient services at NewYork-Presbyterian Hospital, including the intensive care unit and cardiac units.For more information visit nyp.org/Advances

  --------  

  16:44

  --------

  16:44

More Education podcasts

Trending Education podcasts

About Advances in Care

Advances in Care: Podcasts in Family